AUPH Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.74%, SMA50 -7.24%, SMA200 14.38%). The stock’s 14-day RSI is 37.46 (weak momentum), while the ATR of 0.5 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.54% below its high and over 113.28% above its low. Average 10-day trading volume of 1.03 million shares is in line with the 3-month average of 1.02 million, indicating normal recent market interest.

Aurinia Pharmaceuticals Inc. has 131.84 million shares outstanding. The public float is 128.86 million shares, elevated short interest at 7.86% of float. This equals 9.46 million shares. The short ratio is 10.43 days. Institutional investors hold 54.66% of the float. Insiders own 7.14%. TANG KEVIN holds 11.33 million shares, Greenleaf Peter has 1.52 million shares and Donley Matthew Maxwell has 584.07 thousand shares.

Wall Street analysts project EPS growth of 197.2% annually over the next five years. The latest quarter delivered EPS of $0.23. The next quarter is forecast at $0.22. Next year's EPS is expected at $29.71. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $21.00 to $9.00. The high target offers 48.2% upside. The low target suggests -36.49% downside. The mean target is $15.60. This offers 10.09% upside. Aurinia Pharmaceuticals Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 28.89%. The prior quarter beat by -5.88%. Over the last six quarters, Apple has recorded several small beats. These include -49.9% in August 01, 2024.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed at $14.17 USD, gaining $0.20 (1.43%) from the previous close of $13.97. The stock is currently mid-range between its 52-week high and low $6.83 and $16.54. With a market capitalization of about $1.87 billion, Aurinia Pharmaceuticals Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.51). Key stats such as the average daily volume over the past year has been around 1.05 million shares, trading with heavier-than-usual volume. Headquartered in Edmonton, BC, Aurinia Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Peter S. Greenleaf, the company employs approximately 130 people and listed since September 03, 2014. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.

Aurinia Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.60. This means the shares are trading above this model’s fair value.

Aurinia Pharmaceuticals Inc. trades at a P/E ratio of 6.59, slightly below the S&P 500 average, with a price-to-sales ratio of 6.57 and a price-to-book ratio of 3.26 trading at moderately above to book value. The P/FCF stands at 13.72, also above market averages.

Our AI price prediction model suggests that Aurinia Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.92%, with price expected at $14.04 by March 13, 2026, within a range of $13.83 to $14.24 3-Month Outlook: Projected fall of -24.77%, reaching $10.66 by May 28, 2026, with a range of $10.31 to $10.97. 1-Year Outlook: Projected gain of 153.99%, with price at $35.99 by February 26, 2027, within a range of $37.11 to $40.56.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares are flat -7.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Aurinia Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of 6.59. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $16.80, suggesting 18.56% upside. Our AI forecast model points to short-term weakness (-0.92% over two weeks), a medium-term fall (-24.77% over three months), and a longer-term gain (153.99% over one year), with expected trading ranges indicating moderate volatility.